A Prospective, Single-arm, Multi-centre, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions.

Trial Profile

A Prospective, Single-arm, Multi-centre, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use
  • Acronyms Morpheus
  • Sponsors Meril Life Sciences
  • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 1 May 2020 to 1 Dec 2020.
    • 11 Apr 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2018.
    • 11 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top